Lundbeckfonden Ventures and Alexandria Venture Investments both backed a series A round for tumour and endocrine disease drug developer Tiburio.
US-based biopharmaceutical startup Tiburio Therapeutics has launched with $31m in series A funding from investors including pharmaceutical firm Lundbeck and life sciences real estate investment trust Alexandria Real Estate Equities.
Venture capital firms New Enterprise Associates (NEA) and Longitude Capital also took part. Lundbeck participated through corporate venture capital arm Lundbeckfonden Ventures while Alexandria Real Estate Equities invested through its Alexandria Venture Investments vehicle.
Tiburio is developing a drug that aims to treat non-functioning pituitary adenoma (NFPA), a type of…
